← Browse by Condition
Medical Condition

respiratory syncytial virus rsv

Total Trials
4
Recruiting Now
4
Trial Phases
EARLY_Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for respiratory syncytial virus rsv sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — respiratory syncytial virus rsv Clinical Trials

How many clinical trials are currently recruiting for respiratory syncytial virus rsv?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for respiratory syncytial virus rsv, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for respiratory syncytial virus rsv?
respiratory syncytial virus rsv research spans Phase 1 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a respiratory syncytial virus rsv clinical trial?
Eligibility criteria for respiratory syncytial virus rsv trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 3
1
Top Sponsors
Shanghai Institute Of Biological Products 1 trial
AstraZeneca 1 trial
Pfizer 1 trial
CorEvitas 1 trial

Recruiting Clinical Trials

NCT07106918 EARLY_Phase 1
Recruiting

A Clinical Trial of SIBP-A16 Injection in Healthy Adults

Enrollment
140 pts
Location
China
Sponsor
Shanghai Institute Of Biologic...
View Trial →
NCT06851806
Recruiting

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Enrollment
138 pts
Location
India
Sponsor
AstraZeneca
View Trial →
NCT07543380 Phase 3
Recruiting

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

Enrollment
130 pts
Location
Japan
Sponsor
Pfizer
View Trial →
NCT06521944
Recruiting

RSV Vaccine Pregnancy Registry

Enrollment
2,062 pts
Location
United States
Sponsor
CorEvitas
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology